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includes diagnosis and subsequent treatment. Whilst there are differences in the
results between countries due to coding practices and population, the results are
consistent over time and suggest a role for diagnostic interventions which can
speed up diagnosis, thus ensuring more appropriate patient management at an
earlier stage.
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OBJECTIVES: Atrial fibrillation (AF) is an arrhythmia that progressively worsens
and is characterized by uncoordinated atrial activation involving a rapid and irreg-
ular heart rate (Fuster et al., 2006). AF patients are likely to have concomitant
congestive heart failure (CHF) and stroke (Lee et al., 2008). The prevalence of AF in
adults 65 years is 5-6%, increasing with age (Go et al., 2001). The purpose of this
study was to estimate the economic burden of AF in selected developed countries
based on prevalence and direct health care costs.METHODS:The economic burden
of AF in Belgium, Japan, The Netherlands, and Spain was modeled based on prev-
alence rates identified via a literature search. Annual probabilities of receiving
health care treatment and associated costs for AF, stroke and CHF, and related
disability costs were included in the model. If cost data were unavailable, the costs
were imputed based on the ratio of annual per capita health expenditures between
the US and the country of interest. Cost estimates were calculated in 2011 euros.
RESULTS: The prevalence of AF in adults aged 65 in the countries studied was:
59,600 in Belgium; 83,400 in the Netherlands; 182,000 in Spain; and 593,400 in Japan.
The estimated annual economic burden of AF was: EUR 181.2 in Belgium; 256.6 in
the Netherlands; 333.5 in Spain; and 1,722.5 in Japan (in millions). CONCLUSIONS:
The economic burden of AF in developed countries is substantial, and is expected
to grow as the population ages. Early detection and appropriate management of AF
may help reduce this economic burden.
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OBJECTIVES: To evaluate the burden of SSI (surgery site infection) in common
surgeries in Korea. The considered surgeries: gastrointestinal surgery, Coronary
Artery Bypass Grafting (CABG) and orthopaedic surgery represent the procedures
with high, medium and low SSI risk. METHODS: The analysis was conducted from
the hospital perspective. Costs were evaluated on the basis of Health Insurance
Review Agency (HIRA) data. Risk of SSI and the influence of SSI on hospital length
of stay (LOS) were calculated according to studies from a review Lee 2011. The
influence of prolonged hospitalization on expenses was obtained with an assump-
tion that the costs are evenly distributed during the stay. RESULTS: The risk of SSI
depends on surgery type. Among the procedures considered, the highest SSI rate –
5% was related to gastric surgery and the lowest SSI rate – 1% to knee replacement.
LOS in case of SSI is prolonged for about 60%. According to current data on hospi-
talization cost from HIRA, the influence of SSI on providers’ budget could be sub-
stantial. The estimated increase in hospitalization cost induced by SSI is about 3.9
million won (2.700 €) for gastrointestinal surgery, 4.3 million won (3.000 €) for or-
thopaedic surgery and even 10.0 million won (6.900 €) for CABG. Halving the SSI rate
would reduce the mean expenses for about 1%. CONCLUSIONS: The burden of SSI
in Korea is high as SSI implies the significant prolongation of LOS. The detailed
analysis should then be carried out in order to define the possible ways of mini-
mizing the infection risk. The possible range of relatively non expensive risk-re-
ducing interventions which may imply the substantial reduction of SSI rate include
the use of antimicrobial sutures, antibiotics prophylactics, a safety checklist and
other. The increased cost of SSI prevention would be probably broadly offset by the
decreased costs of hospital stay.
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OBJECTIVES: To assess the cost of using continuous subcutaneous insulin infusion
(CSII) to treat children with diabetes and to compare it with the changes in HbA (1c)
and BMI. The study was performed from the point of view of the health insurance
fund and patients. METHODS: A combined retrospective and prospective analysis
of the patients’ records after the introduction of CSII was performed. Cost of CSII,
blood glucose monitoring system and strips was calculated. The primary outcome
observed was the variation in HbA(1c) and the secondary was the BMI change.
RESULTS: Subcutaneous insulin infusion (CSII) systems are of a limited usage be-
cause they are not reimbursed by the health insurance fund in the country. The
university pediatric clinic is introducing them on the request of the parents and
only 30 children apply such. 11 children with diabetes type 1 during the period
1999–2011 were observed (mean age 10 years, mean duration of the disease is 7
years, average usage of CSII - 3 years). The CSII price is 3896 Euro and compared to
the duration of usage it costs 1292 euro per patient per year. The blood glucose
monitoring system costs 20 Euro and for the duration of the disease - 4.96 Euro per
patient per year. The test stripes costs 533 Euro/ year (1100 stripes per year) and
their average cost according to the duration of the disease is 3779.45 Euro since
diagnosis. Thus the total yearly cost weighed with the duration of the disease is
1850 Euro (30% reimbursed). The average improvement of HbA (1c) after the CSII
introduction is 1.72 and the average BMI was 37.03. CONCLUSIONS: Improvements
in glycemic control associated with CSII led to reduced HbA(1c) that can guarantee
good diabetes management, but its control over BMI in growing children is still
unclear.
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OBJECTIVES: The frequency of newly diagnosed thyroid nodule is increasing, prob-
ably because of the widespread use of ultrasonography in Korea. However, there
are few researches about the incidence of thyroid cancer in patient with thyroid
nodules using national representative data. This study is performed to investigate
the incidence of thyroid cancer and medical costs among patients who were newly
diagnosed as thyroid nodule in South Korea. METHODS: We analyzed national
health claim database including all hospital records covering almost every popu-
lation by national health insurance system. We selected patients aged 20-120 years
old with thyroid nodules using ICD-10 codes of D34*, E041, E042 in 2008. We ex-
cluded all patients who were previously reported to have a thyroid nodule or any
type of cancer including thyroid cancer between 2006 and 2007. We conducted a
follow-up survey of the selected subjects on the national health claim database at
least for 2 years after diagnosis. RESULTS: We identified 283,844 eligible patients
with thyroid nodules. Their mean age 4813.2, and 234,388 (82.58%) subjects were
female. During median follow-up of 2.4 years, 21,538 (7.6%) Lower age, history of
thyroid disease or diabetes was associated with the risk of thyroid cancer. Mean
direct medical cost per patient paid by national insurer or shared by patient related
with newly diagnosis of thyroid nodules were about 475 Euros during follow up.
The medical cost of thyroid nodules subjects was 271 Euros, and it was especially
higher in patients with thyroidectomy (1378 Euros). CONCLUSIONS: In Korea, the
incidence of thyroid cancer was relatively higher, while the medical cost was much
lower than other countries, suggesting that careful follow-up for thyroid nodules
requited in Korea. Further study is needed to identify the risk factors of thyroid
cancer in patients with thyroid nodules.
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OBJECTIVES: Cervical degenerative disc disorders are increasingly common in
adults. Patients refractory to conservative therapy require surgery for relief of pain.
This micro-costing study sought to compare actual costs of index hospitalization
versus DRG revenue for cervical disc arthroplasty (CDA) in order to explore the
financial profit or loss of this emerging intervention for German hospitals.
METHODS:As published data is scarce, detailed in-hospital resource utilization for
1-level or 2-level CDA was mainly based on information supplied by three experi-
enced neurosurgeons from private and public German hospitals. Where available,
these estimates were compared and calibrated with existing data. Unit costs col-
lected from hospital accounting departments and information from German refer-
ence cost databases and the published literature were subsequently assigned to the
resource use items for the calculation of actual hospital costs associated with CDA.
RESULTS: Average total per-patient hospital costs were estimated at €5,930 for
1-level and €8,768 for 2-level arthroplasty. Most important cost drivers were the
costs of materials & disposables required for the intervention (relative contribution
to total hospital costs for 1-level CDA: 44%, for 2-level CDA: 58%), followed by
hospital ward costs (27%, 18%), use of operating and recovery room (15%, 13%),
OR-team (8%, 7%), and diagnostic examinations (6%, 4%). With current G-DRG pay-
ments for mono-segmental CDA (€6,620) and bi-segmental CDA (€9,815), German
hospitals can achieve average earnings of €690 (1-level CDA) and of €1,047 (2-level
CDA) when performing this emerging disc replacement technique.CONCLUSIONS:
Our costing study indicates that 1- or 2-level CDA represents a feasible and finan-
cially sustainable surgical therapy for German hospitals. First evidence from the
literature also tends to show that CDA is associated with additional long-term
benefits in terms of reduced rates of disc reoperations compared to conventional
anterior cervical discectomy and fusion.
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OBJECTIVES: To estimate the costs and benefits of diagnosis strategies using DNA
testing for mucinous pancreatic cysts (MPCs). METHODS: A decision tree was con-
structed that compared three diagnostic strategies for pancreatic cysts: 1) endo-
scopic ultrasound-guided fine needle aspiration (EUS-FNA) with cyst fluid testing
for carcinoembryonic antigen (CEA); 2) strategy 1DNA testing if insufficient fluid
for a CEA; 3) strategy 2DNA testing if the CEA is indeterminate. Probabilities of
insufficient fluid, positive, negative, and, indeterminate CEA results, and positive
DNA results given insufficient fluid or indeterminate results were calculated from
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a database of 286 patients receiving EUS-FNA and the DNA test. Patients who had
pancreatic cysts and were not indicated for surgery by cytology alone were divided
into the four possible CEA-result groups using criteria that specifies5 is negative,
and 192 positive. The DNA test was considered positive if any of three compo-
nents (DNA quantity, K-ras mutation, and multiple allelic imbalance mutations)
were positive. RESULTS: Based on the database, 38.5% had insufficient fluid for
CEA. Of CEAs, 50% were positive, 21.6% negative, and 28.4% indeterminate. Proba-
bilities of a positive DNA test were 6.9% in patients with negative, 36.8% with
indeterminate, and 55.2% with positive CEAs, and 35.7% in patients with insuffi-
cient fluid. Including costs of cytology but not the EUS-FNA, costs were $381, $1575,
and $2642 per patient for the three strategies. Assuming the DNA is not specific
enough for a negative diagnosis, the costs per MPC diagnosis are $866, $2716, and
$4128 with 44%, 58%, and 64% being diagnosed. Positive diagnosis results in annual
follow–up with potential for surgical resection. CONCLUSIONS: Scenarios in which
negative DNA tests forego or reduce frequency of follow-up with minimal increase
in cancer risk are potentially cost-effective. However, if positive and indeterminate
diagnoses are treated similarly, the DNA test cost cannot be justified.
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OBJECTIVES: In the UK, anti-angiogenesis (AA) drugs (e.g. bevacizumab) have not
been accepted as good value for money within the general metastatic breast cancer
(MBC) population. However, it may benefit some subpopulations within MBC. An-
giogenesis-specific imaging tests (A-IT) under development have the potential to
offer earlier, accurate determination of response to AA therapies for MBC patients,
and lower treatment costs.METHODS:A decision-tree-based model was developed
to estimate the likely economic impact of A-IT from start of AA therapy through to
progression of disease. Key decision nodes were presence/absence of A-IT, sensi-
tivity/specificity (SE/SP) of A-IT, clinician adherence to test results and treat/no
treat decision. Key model inputs (and base case values): 1) median time to progres-
sion [TTP] for current MBC patients on AA therapies (9.5 months); 2) median TTP for
A-IT identified responders (13 months); 3) costs of bevacizumab, one cycle (£3,591);
4) costs of hemorrhaging, per event (£9,681); 5) per patient costs for diagnostic
(£3,826); 6) estimated SE/SP of diagnostic – 95%/75%; 7) clinician adherence to test
results (75%). RESULTS: Based on a hypothetical cohort of MBC patients, base case
results indicate that use of A-IT after just one cycle of AA therapy results in savings
of £3,570 per patient versus a scenario where A-IT was not used. One-way thresh-
old sensitivity analysis shows A-IT is cost-saving if SP  62% or when clinician
adherence is 63%. Results were insensitive to changes in SE. CONCLUSIONS:Use
of A-IT could allow for cost-effective use of AA therapies in subgroups of MBC
patients due to the earlier, more accurate determination of clinical benefit. Further
research is required to assess if A-IT allows AA therapy to become acceptably
cost-effective treatment for general MBC in the UK.
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OBJECTIVES: Patients with high risk early breast cancer (BC) frequently have adju-
vant therapy that includes taxane treatment (TAX) with a 28% reduction in risk of
relapse (BCIRG 001). TAX is associated with considerable toxicities which impact
quality-of-life and only a minority of patients derive benefit from the regimen.
Biomarkers to predict TAX-response may improve the equation of treatment/ad-
verse events costs with the benefits and risks to patients. Our objective is to exam-
ine the economic impact of adding a predictive TAX test for BC in a UK health care
setting. METHODS: A predictive model estimated the potential cost offsets of test-
ing a cohort of BC pts with a biomarker to guide therapy selection vs. no pretesting.
The no biomarker test group received 6 cycles of 3 weekly TAC: docetaxel (50mg/
m2) doxorubicin (50mg/m2), cyclophosphamide (500mg/m2) (cost £5944 generic
prices). In the biomarker tested (cost £606) cohort, only those with biomarker over-
expression received TAC. Assuming test predictivity of 70-90%, those found with-
out over-expression (50.3% - 64.7% based upon 71.9% with no improved disease free
survival from TAX trial findings, were treated with NICE guideline-recommended
FEC-60 X 6 cycles (£2213)). Each group accrued appropriate related therapy, toxicity
and biomarker test costs, with all costs taken from published sources. RESULTS:At
70-90% predictive, the model estimated £2991–£3846 of TAC therapy costs/patient
could be avoided along with £350-£450 of toxicity-related costs with the biomarker.
Taking alternative therapies and toxicities into account, potential cost offsets were
£2413-£3276. Patients without biomarker over-expression avoided TAC toxicities
and associated quality-of-life impacts. CONCLUSIONS: Applying a biomarker test
to identify women likely to respond to TAX appears to save drug costs and avoid
TAX-related toxicities.
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OBJECTIVES: Approximately 20% of metastatic renal cell carcinoma (mRCC) pa-
tients receiving 1st line (1LT) sunitinib experience disease progression (PD) identi-
fied by RECIST at 90 days post 1LT initiation. Earlier PD identification would mini-
mize futile1LT, facilitating a switch to potentially more effective 2nd line therapy.
Current research is evaluating biomarkers that identify rapid PD (rPD). This study’s
goal was to estimate the economic impact of utilizing an angiogenesis-specific
imaging (AI) biomarker for early PD identification. METHODS: An economic model
for mRCC patients receiving 1LT sunitinib from a UK National Health System per-
spective was developed with a 90 day time horizon. Comparator arm used RECIST
monitoring; the intervention arm an AI biomarker. Inputs included: timing of PD
assessment (day 14 for AI; day 90 for RECIST); sunitinib costs (£1,569 for 14 days;
£6,950 for 90 days); other 1LT costs (£468 for 14 days; £1,861 for 90 days); and rPD
rate of 20%. Outcomes included incremental length of futile 1LT and costs for AI vs.
RECIST. RESULTS: For AI sensitivity of 50%, a 38 day reduction in futile 1LT could be
achieved per rPD patient by using AI vs. RECIST (AI sensitivity of 75% or 100%
yielded 57 and 76 fewer days). Incremental cost savings reflecting resources that
could be freed up for AI utilization across all mRCC patients was £677, £1,016 and
£1,355 per patient for AI sensitivity of 50%, 75% and 100%. CONCLUSIONS: Pro-
longed therapy exposes non-responding patients to risks without potential clinical
benefit and results in misallocated health care resources which could be directed
elsewhere. Results of this study suggest that a diagnostic test enabling early PD
identification may reduce futile 1LT and its negative clinical/economic conse-
quences. Further research should evaluate additional benefits of early PD identifi-
cation, including improved patient quality of life and/or better clinical outcomes of
subsequent therapies.
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OBJECTIVES: Self-Monitoring of Blood Glucose (SMBG) is considered as a key factor
in management of people with diabetes which is a growing and cost demanding
health problem. The purpose of this study was to investigate the effect of compre-
hensive patient management using structured SMBG on metabolic control as well
as its cost consequence analysis. METHODS: Sixty subjects were recruited in an
observational study for a period of 6 months. They were provided with the ACCU-
CHEK 360° View tool to fill in the values of the 7-point blood glucose profiles in three
consecutive days during the study on a monthly basis. Changes in metabolic con-
trol were assessed by HbA1c and lipid profile measurement at the beginning and at
the end of the study. In addition, cost consequence analysis was done considering
different level of health care professionals with or without insurance coverage. The
Average Cost Effectiveness Ratio (ACER) as well as Cost Benefit Analysis (CBA) were
calculated and compared. RESULTS: The analysis showed significant reduction in
HbA1c during the 6-month period in all subjects (P0.000). Furthermore, a positive
effect was observed on lipid profile. The cost of endocrinologist’s visit in private
sector was estimated to be 265.76 USD while this figure was 149.15 USD for general
practitioner in public sector with insurance coverage. Total complications and
mortality cost saving was 154.8 USD. The lowest ACER was calculated for the in-
tervention done by general practitioner in public sector with insurance coverage.
CONCLUSIONS: Structured SMBG results in significant improvement of glycemic
status. Moreover, it is cost beneficial in public sector with insurance coverage. It
seems that general practitioner visits with insurance coverage is the most afford-
able option for people with type 2 diabetes.
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OBJECTIVES: The purpose of this medico-economic study is to estimate cost-effec-
tiveness impact of treating the patients suffering from venous leg ulcers in France.
Outpatient treatment with soft-adherent foam dressing with TLC-NOSF a healing
accelerator technology (Lipido-Colloid Technology, TLC, with Nano-OligoSaccha-
ride Factor, NOSF) was compared to the identical dressing without NOSF com-
pound (neutral foam dressing).METHODS:A lifetime Markov model based on three
states: “Patient with more than 6 months venous leg ulcer”, “Patient with healing
ulcer” and “Death”. The healing process is represented by a law of Gompertz. The
probability of recurrences is considered. Monte Carlo simulation of 1000 patients
was applied to compare face to face the situations which were not experimentally
tested. An intermediate endpoint of effectiveness was healing rate of ulcers during
8 weeks. A final health outcome was life-years gained without ulcers. We have
estimated the direct costs associated with material costs, medical consultation and
nursing care. This evaluation takes into account both health insurance and health
care system perspectives in France. Clinical and economic outcomes were dis-
counted at 4%. RESULTS: The number of life-years gained without ulcer is 5.8
(CI95%: [5.5;6.0]) years comparing with the dressing without NOSF. Additional
QALY gain is 1.3 [CI95%: 1.2; 1.3]. According to health care system perspective, the
mean cost per patient at lifetime period is €20119,322 [CI95%: €8,725; €9,920] com-
paring with €18,352 [CI95%: €17,807; €18,897] using the dressing of reference. The
probabilistic sensitivity analysis of 10,000 bootstrapping samples was performed
comparing two strategies. The estimated probability shows 100% of acceptability of
the treatment with TLC-NOSF technology. CONCLUSIONS: According to the base
case hypotheses the innovational strategy TLC-NOSF is more effective and less
costly than the reference dressing (neutral foam dressing).
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